WINTON GROUP Ltd Purchases 136,820 Shares of Pediatrix Medical Group, Inc. $MD

WINTON GROUP Ltd lifted its position in shares of Pediatrix Medical Group, Inc. (NYSE:MD) by 174.8% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 215,096 shares of the company’s stock after buying an additional 136,820 shares during the period. WINTON GROUP Ltd’s holdings in Pediatrix Medical Group were worth $3,603,000 at the end of the most recent quarter.

A number of other hedge funds have also modified their holdings of the company. Royal Bank of Canada lifted its stake in Pediatrix Medical Group by 23.8% in the 1st quarter. Royal Bank of Canada now owns 22,097 shares of the company’s stock valued at $320,000 after acquiring an additional 4,247 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its stake in shares of Pediatrix Medical Group by 4.6% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 51,253 shares of the company’s stock worth $743,000 after acquiring an additional 2,251 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its holdings in shares of Pediatrix Medical Group by 4.7% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 268,506 shares of the company’s stock valued at $3,891,000 after purchasing an additional 12,171 shares during the last quarter. Atria Investments Inc raised its holdings in shares of Pediatrix Medical Group by 9.4% in the second quarter. Atria Investments Inc now owns 16,435 shares of the company’s stock valued at $236,000 after purchasing an additional 1,411 shares during the last quarter. Finally, Connor Clark & Lunn Investment Management Ltd. lifted its position in shares of Pediatrix Medical Group by 284.6% in the second quarter. Connor Clark & Lunn Investment Management Ltd. now owns 175,987 shares of the company’s stock worth $2,525,000 after purchasing an additional 130,226 shares in the last quarter. 97.71% of the stock is currently owned by institutional investors.

Insider Activity at Pediatrix Medical Group

In other news, CEO Mark S. Ordan sold 23,000 shares of the business’s stock in a transaction dated Monday, December 15th. The shares were sold at an average price of $22.41, for a total transaction of $515,430.00. Following the transaction, the chief executive officer directly owned 302,805 shares in the company, valued at $6,785,860.05. The trade was a 7.06% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 0.90% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

Several research analysts recently commented on MD shares. Zacks Research cut shares of Pediatrix Medical Group from a “strong-buy” rating to a “hold” rating in a report on Friday, January 23rd. UBS Group lowered their price target on shares of Pediatrix Medical Group from $23.00 to $22.00 and set a “neutral” rating on the stock in a research note on Tuesday, February 24th. Deutsche Bank Aktiengesellschaft set a $19.00 price target on shares of Pediatrix Medical Group in a research report on Friday, February 20th. Weiss Ratings restated a “hold (c+)” rating on shares of Pediatrix Medical Group in a research note on Monday, December 29th. Finally, Truist Financial decreased their price objective on Pediatrix Medical Group from $24.00 to $21.00 and set a “hold” rating for the company in a report on Thursday, February 19th. One research analyst has rated the stock with a Buy rating and five have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average target price of $19.80.

Pediatrix Medical Group Trading Up 1.8%

NYSE MD opened at $20.10 on Tuesday. Pediatrix Medical Group, Inc. has a 12 month low of $11.84 and a 12 month high of $24.99. The company has a current ratio of 1.66, a quick ratio of 1.66 and a debt-to-equity ratio of 0.66. The stock has a 50 day moving average of $21.08 and a 200-day moving average of $19.98. The company has a market cap of $1.67 billion, a PE ratio of 10.36 and a beta of 0.79.

Pediatrix Medical Group (NYSE:MD) last issued its earnings results on Thursday, February 19th. The company reported $0.50 earnings per share for the quarter, missing analysts’ consensus estimates of $0.53 by ($0.03). Pediatrix Medical Group had a return on equity of 19.59% and a net margin of 8.64%.The firm had revenue of $493.77 million for the quarter, compared to analyst estimates of $486.23 million. During the same quarter in the previous year, the firm posted $0.51 earnings per share. Pediatrix Medical Group’s quarterly revenue was down 1.7% on a year-over-year basis. On average, equities research analysts anticipate that Pediatrix Medical Group, Inc. will post 1.38 EPS for the current fiscal year.

Pediatrix Medical Group Profile

Pediatrix Medical Group, Inc (NYSE:MD) is a national physician-led medical group specializing in high-acuity newborn, maternal-fetal and pediatric subspecialty care. Headquartered in Sunrise, Florida, the company delivers clinical services through hospital-based physician staffing, advanced practitioner support and telemedicine programs. Its core specialties include neonatology, maternal-fetal medicine, pediatric cardiology, pediatric critical care, pediatric emergency medicine and anesthesiology.

Founded in 1979 and formerly known as MEDNAX, the company rebranded as Pediatrix Medical Group in 2022 to align its corporate identity with its primary clinical offerings.